Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.31 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779216 | 0.87 | CSNK1D (0.39) | MCHR1LMNAALKL3MBTL1MAP3K5 | |
| SCHEMBL18779222 | 0.85 | MCHR1 (0.35) | MCHR1ALKL3MBTL1NTRK1INSR | |
| SCHEMBL18791921 | 0.84 | MCHR1 (0.36) | MCHR1ALKNTRK1INSRLCK | |
| SCHEMBL18779202 | 0.83 | ALK (0.34) | MCHR1ALKNTRK1INSRLCK | |
| SCHEMBL18791919 | 0.82 | MCHR1 (0.37) | MCHR1SMN1; SMN2ALKNTRK1INSR | |
| SCHEMBL21354661 | 0.82 | GPR55 (0.34) | MCHR1USP2MAP3K5 | |
| SCHEMBL30315395 | 0.82 | GPR55 (0.34) | MCHR1USP2MAP3K5 | |
| SCHEMBL21354649 | 0.81 | RPS6KA3 (0.33) | MCHR1ALKNTRK1INSRLCK | |
| SCHEMBL21354651 | 0.81 | RPS6KA3 (0.33) | MCHR1ALKNTRK1INSRLCK | |
| SCHEMBL30315405 | 0.81 | RPS6KA3 (0.33) | MCHR1ALKNTRK1INSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | MCHR1 3930/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | MCHR1 3930/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | MCHR1 3930/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | MCHR1 3930/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.